Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shigella flexneri 2a InvaplexAR
- Development stage
- Phase 1
- Lead developer
- Walter Reed Army Institute of Research
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
Shigella flexneri 2a InvaplexAR is an artificial Invaplex vaccine, developed as a subunit approach, designed to prevent Shigellosis and Bacillary Dysentery. It induces immune responses against serotype-specific lipopolysaccharide (LPS) and conserved invasion plasmid antigen (Ipa) proteins B and C of Shigella flexneri 2a. The vaccine is administered intranasally and has completed a Phase 1 clinical trial to assess its safety and immunogenicity.
02
Targets
IpaB (Invasion plasmid antigen B)IpaC (Invasion plasmid antigen C)S. flexneri 2a LPS (Shigella flexneri serotype 2a lipopolysaccharide)
Beyond the preview
Go deeper on Shigella flexneri 2a InvaplexAR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shigella flexneri 2a InvaplexAR.